e.valuation, clinical: tackle attrition
Concluding on inclusion criteria in clinical trials and having all data in hand for relevant post-hoc analysis are central components for leveraging on clinical studies, hence bringing novel medication to most beneficial use in the routine clinical setting. Enhanced molecular phenotype profiling, predictive biomarkers on drug response, and molecular indicators educating on affecting mechanisms prone to triggering side effects are all to be taken care of in the clinical study setting.
e.valuation application scenarios in clinical stage asset testing include:
- derive biomarker candidate panels for molecular phenotype profiling/drug response
- evaluate drug-to-phenotype molecular interference, focus on side effects
- increase probability of technical success
e.valuation provides dedicated workflows acting at the interface of drug mechanism of action and disease pathophysiology, profiled by selected biomarker candidates: the fundament of clinical trial enrichment strategies.